Market Place
Sourcing Support
Longeveron® Announces Q3 2024 Financial Results & Business Update
12 Nov 2024 //
GLOBENEWSWIRE
Longeveron® Appoints Devin as Chief Technology Officer & SVP of CMC
11 Nov 2024 //
GLOBENEWSWIRE
Longeveron® to Report Q3 2024 Results on Nov 12
04 Nov 2024 //
GLOBENEWSWIRE
Longeveron Presents Lomecel-B™ Data for Alzheimer’s at CTAD24
29 Oct 2024 //
GLOBENEWSWIRE
Longeveron® Presents Lomecel-B™ Data in HLHS at CHSS Meeting
27 Oct 2024 //
GLOBENEWSWIRE
Longeveron Lomecel-B Data In Alzheimer`s Selected For CTAD24
14 Oct 2024 //
GLOBENEWSWIRE
Longeveron Lomecel-B Data Selected For CHSS 51st Annual Meeting
09 Oct 2024 //
GLOBENEWSWIRE
Longeveron To Present At UBS Virtual Organ Restoration Day
07 Oct 2024 //
GLOBENEWSWIRE
Longeveron® Joins 3rd Annual ROTH Healthcare Conference
02 Oct 2024 //
GLOBENEWSWIRE
Longeveron To Attend Cell & Gene Meeting On The Mesa
26 Sep 2024 //
GLOBENEWSWIRE
Longeveron Announces Positive FDA Meeting for Lomecel-B in HLHS
03 Sep 2024 //
GLOBENEWSWIRE
Longeveron to Present at H.C. Wainwright Annual Global Investment Conference
26 Aug 2024 //
GLOBENEWSWIRE
Longeveron To Present At H.C. Wainwright Global Investment Conference
26 Aug 2024 //
GLOBENEWSWIRE
Longeveron Announces Q2 2024 Financial Results And Business Update
14 Aug 2024 //
GLOBENEWSWIRE
Longeveron To Report Q2 2024 Results On August 14
05 Aug 2024 //
GLOBENEWSWIRE
Longeveron Shares CLEAR MIND Phase 2a Trial Data On Lomecel-B For Alzheimer`s
28 Jul 2024 //
GLOBENEWSWIRE
Longeveron Closes $9.0M Registered Direct Offering At Market Price
19 Jul 2024 //
GLOBENEWSWIRE
Longeveron Announces $9.0 Million At-Market Offering
18 Jul 2024 //
GLOBENEWSWIRE
Longeveron`s Lomecel-B Gets FDA Fast Track For Mild Alzheimer`s
17 Jul 2024 //
GLOBENEWSWIRE
FDA Grants Longeveron`s Lomecel-B RMAT Status For Mild Alzheimer`s
10 Jul 2024 //
GLOBENEWSWIRE
Neha Motwani Elected to Longeveron® Board of Directors
09 Jul 2024 //
GLOBENEWSWIRE
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
08 Jul 2024 //
GLOBENEWSWIRE
Longeveron Raises $4.4 Million in Gross Proceeds from Warrant Transaction
18 Jun 2024 //
GLOBENEWSWIRE
Longeveron Announces Exercise Of Warrants For $4.4 Million Gross Proceeds
17 Jun 2024 //
GLOBENEWSWIRE
Longeveron To Present At Virtual Life Sciences Investor Forum On June 20, 2024
17 Jun 2024 //
GLOBENEWSWIRE
Longeveron® Announces Completion of Meeting forOn-going Pha2b Trial Lomecel-B™
11 Jun 2024 //
GLOBENEWSWIRE
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024
10 Jun 2024 //
GLOBENEWSWIRE
Longeveron Announces CDMO Business, First Contract
03 Jun 2024 //
GLOBENEWSWIRE
Longeveron® to Attend BIO International Convention 2024
28 May 2024 //
GLOBENEWSWIRE
Longeveron Announces Q1 2024 Results, Business Update
14 May 2024 //
GLOBENEWSWIRE
Longeveron Announces Board of Directors Planned Transitions
10 May 2024 //
GLOBENEWSWIRE
Longeveron Q1 2024 Results, Conference Call On May 14
02 May 2024 //
GLOBENEWSWIRE
Longeveron to Present at the Planet MicroCap Showcase
25 Apr 2024 //
GLOBENEWSWIRE
Longeveron Raises $11.4M From Warrant Exercise, Public Offering
18 Apr 2024 //
GLOBENEWSWIRE
Longeveron Announces $6.2M from Warrant Exercises
17 Apr 2024 //
GLOBENEWSWIRE
Longeveron`s Alzheimer`s Data At AAIC Featured Session
15 Apr 2024 //
GLOBENEWSWIRE
Longeveron Announces Closing of $5.2 Million Public Offering
11 Apr 2024 //
GLOBENEWSWIRE
Longeveron Issues Letter to Shareholders
08 Apr 2024 //
GLOBENEWSWIRE
Longeveron Announces Pricing of $5.25 Million Public Offering
08 Apr 2024 //
GLOBENEWSWIRE
Longeveron Announces 1-for-10 Reverse Stock Split
19 Mar 2024 //
GLOBENEWSWIRE
With cash runways ending, Nicox and Longeveron plan layoffs
28 Feb 2024 //
FIERCE BIOTECH
Longeveron Reports Year-End 2023 Results and Provides Corporate Update
27 Feb 2024 //
GLOBENEWSWIRE
Longeveron to Report Year-End 2023 Results
21 Feb 2024 //
GLOBENEWSWIRE
Longeveron Receives Notice of United States Patent Allowance
29 Jan 2024 //
GLOBENEWSWIRE
Longeveron Announces Closing of $2.36 Million Registered Direct Offering
22 Dec 2023 //
GLOBENEWSWIRE
Longeveron Announces $2.36 Million Registered Direct Offering
21 Dec 2023 //
GLOBENEWSWIRE
UPDATE -- Longeveron Announces $2.36 Million Registered Direct Offering
21 Dec 2023 //
GLOBENEWSWIRE
Longeveron Announces Results from the CLEAR MIND Phase 2a Trial of Lomecel-B
20 Dec 2023 //
GLOBENEWSWIRE
Long-term Survival Data from Longeveron™s ELPIS 1 Trial Presented
11 Nov 2023 //
GLOBENEWSWIRE
Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update
10 Nov 2023 //
GLOBENEWSWIRE
Longeveron to Report Third Quarter 2023 Results
03 Nov 2023 //
GLOBENEWSWIRE
Longeveron Featured in Syndicated Broadcast Highlighting Results from CLEAR MIND
24 Oct 2023 //
GLOBENEWSWIRE
Longeveron Announces Closing of $4 Million Registered Direct Offering
13 Oct 2023 //
GLOBENEWSWIRE
Longeveron Announces $4 Million Registered Direct Offering
12 Oct 2023 //
GLOBENEWSWIRE
Longeveron touts PhIIa Alzheimer`s data, but drug`s future remains murky
05 Oct 2023 //
ENDPTS
Longeveron Issues Letter to Stockholders
11 Sep 2023 //
GLOBENEWSWIRE
Survival Data from Longeveron`s ELPIS 1 Trial Accepted for Presentation
07 Sep 2023 //
GLOBENEWSWIRE
Longeveron to Present at the 25th Annual H.C. Wainwright Global Conference
05 Sep 2023 //
GLOBENEWSWIRE
Longeveron to Participate in the 149th Annual National Investment Conference
29 Aug 2023 //
GLOBENEWSWIRE
Longeveron Rights Offering Subscription Period Begins
22 Aug 2023 //
GLOBENEWSWIRE
